These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 32203954)

  • 1. Reproductive Risk Factors of Inflammatory Breast Cancer according to Luminal, HER2-Overexpressing, and Triple-Negative Subtypes: A Case Comparison Study.
    Mejri N; El Benna H; Rachdi H; Labidi S; Benna M; Daoud N; Hamdi Y; Abdelhak S; Boussen H
    Oncol Res Treat; 2020; 43(5):204-210. PubMed ID: 32203954
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epidemiological risk factors associated with inflammatory breast cancer subtypes.
    Atkinson RL; El-Zein R; Valero V; Lucci A; Bevers TB; Fouad T; Liao W; Ueno NT; Woodward WA; Brewster AM
    Cancer Causes Control; 2016 Mar; 27(3):359-66. PubMed ID: 26797453
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reproductive behaviors and risk of developing breast cancer according to tumor subtype: A systematic review and meta-analysis of epidemiological studies.
    Lambertini M; Santoro L; Del Mastro L; Nguyen B; Livraghi L; Ugolini D; Peccatori FA; Azim HA
    Cancer Treat Rev; 2016 Sep; 49():65-76. PubMed ID: 27529149
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association between common risk factors and molecular subtypes in breast cancer patients.
    Turkoz FP; Solak M; Petekkaya I; Keskin O; Kertmen N; Sarici F; Arik Z; Babacan T; Ozisik Y; Altundag K
    Breast; 2013 Jun; 22(3):344-50. PubMed ID: 22981738
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reproductive Factors and Risk of Luminal, HER2-Overexpressing, and Triple-Negative Breast Cancer Among Multiethnic Women.
    Chen L; Li CI; Tang MT; Porter P; Hill DA; Wiggins CL; Cook LS
    Cancer Epidemiol Biomarkers Prev; 2016 Sep; 25(9):1297-304. PubMed ID: 27307466
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A cumulative index of exposure to endogenous estrogens and breast cancer by molecular subtypes in northern Mexican women.
    Rojas-Lima E; Gamboa-Loira B; Cebrián ME; Rothenberg SJ; López-Carrillo L
    Breast Cancer Res Treat; 2020 Apr; 180(3):791-800. PubMed ID: 32086656
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inflammatory breast cancer: a single centre analysis.
    Gogia A; Raina V; Deo SV; Shukla NK; Mohanti BK; Sharma DN
    Asian Pac J Cancer Prev; 2014; 15(7):3207-10. PubMed ID: 24815472
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reproductive factors and risk of estrogen receptor positive, triple-negative, and HER2-neu overexpressing breast cancer among women 20-44 years of age.
    Li CI; Beaber EF; Tang MT; Porter PL; Daling JR; Malone KE
    Breast Cancer Res Treat; 2013 Jan; 137(2):579-87. PubMed ID: 23224237
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reproductive and hormonal risk factors for luminal, HER2-overexpressing, and triple-negative breast cancer in Japanese women.
    Islam T; Matsuo K; Ito H; Hosono S; Watanabe M; Iwata H; Tajima K; Tanaka H
    Ann Oncol; 2012 Sep; 23(9):2435-2441. PubMed ID: 22328736
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemotherapy response and survival of inflammatory breast cancer by hormone receptor- and HER2-defined molecular subtypes approximation: an analysis from the National Cancer Database.
    Liu J; Chen K; Jiang W; Mao K; Li S; Kim MJ; Liu Q; Jacobs LK
    J Cancer Res Clin Oncol; 2017 Jan; 143(1):161-168. PubMed ID: 27704268
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent Use of Oral Contraceptives and Risk of Luminal B, Triple-Negative, and HER2-Overexpressing Breast Cancer.
    Lorona NC; Cook LS; Tang MC; Hill DA; Wiggins CL; Li CI
    Horm Cancer; 2019 Jun; 10(2-3):71-76. PubMed ID: 30989580
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Distinct outcomes in patients with different molecular subtypes of inflammatory breast cancer.
    Zhou J; Yan Y; Guo L; Ou H; Hai J; Zhang C; Wu Z; Tang L
    Saudi Med J; 2014 Nov; 35(11):1324-30. PubMed ID: 25399208
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Parity, hormones and breast cancer subtypes - results from a large nested case-control study in a national screening program.
    Ellingjord-Dale M; Vos L; Tretli S; Hofvind S; Dos-Santos-Silva I; Ursin G
    Breast Cancer Res; 2017 Jan; 19(1):10. PubMed ID: 28114999
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reproductive Risk Factors Associated with Breast Cancer Molecular Subtypes among Young Women in Northern China.
    Wang JM; Wang J; Zhao HG; Liu TT; Wang FY
    Biomed Res Int; 2020; 2020():5931529. PubMed ID: 32337260
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heterogeneity of epidemiological factors by breast tumor subtypes in Korean women: a case-case study.
    Song N; Choi JY; Sung H; Chung S; Song M; Park SK; Han W; Lee JW; Kim MK; Yoo KY; Ahn SH; Noh DY; Kang D
    Int J Cancer; 2014 Aug; 135(3):669-81. PubMed ID: 24916400
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BMI, reproductive factors, and breast cancer molecular subtypes: A case-control study and meta-analysis.
    Li H; Sun X; Miller E; Wang Q; Tao P; Liu L; Zhao Y; Wang M; Qi Y; Li J
    J Epidemiol; 2017 Apr; 27(4):143-151. PubMed ID: 28142040
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Distinct Reproductive Risk Profiles for Intrinsic-Like Breast Cancer Subtypes: Pooled Analysis of Population-Based Studies.
    Jung AY; Ahearn TU; Behrens S; Middha P; Bolla MK; Wang Q; Arndt V; Aronson KJ; Augustinsson A; Beane Freeman LE; Becher H; Brenner H; Canzian F; Carey LA; ; Czene K; Eliassen AH; Eriksson M; Evans DG; Figueroa JD; Fritschi L; Gabrielson M; Giles GG; Guénel P; Hadjisavvas A; Haiman CA; Håkansson N; Hall P; Hamann U; Hoppe R; Hopper JL; Howell A; Hunter DJ; Hüsing A; Kaaks R; Kosma VM; Koutros S; Kraft P; Lacey JV; Le Marchand L; Lissowska J; Loizidou MA; Mannermaa A; Maurer T; Murphy RA; Olshan AF; Olsson H; Patel AV; Perou CM; Rennert G; Shibli R; Shu XO; Southey MC; Stone J; Tamimi RM; Teras LR; Troester MA; Truong T; Vachon CM; Wang SS; Wolk A; Wu AH; Yang XR; Zheng W; Dunning AM; Pharoah PDP; Easton DF; Milne RL; Chatterjee N; Schmidt MK; García-Closas M; Chang-Claude J
    J Natl Cancer Inst; 2022 Dec; 114(12):1706-1719. PubMed ID: 35723569
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metastatic behavior and overall survival according to breast cancer subtypes in stage IV inflammatory breast cancer.
    van Uden DJP; van Maaren MC; Strobbe LJA; Bult P; van der Hoeven JJ; Siesling S; de Wilt JHW; Blanken-Peeters CFJM
    Breast Cancer Res; 2019 Oct; 21(1):113. PubMed ID: 31623649
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk factors for inflammatory breast cancer and other invasive breast cancers.
    Schairer C; Li Y; Frawley P; Graubard BI; Wellman RD; Buist DS; Kerlikowske K; Onega TL; Anderson WF; Miglioretti DL
    J Natl Cancer Inst; 2013 Sep; 105(18):1373-84. PubMed ID: 24046390
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reproductive and hormonal risk factors for postmenopausal luminal, HER-2-overexpressing, and triple-negative breast cancer.
    Phipps AI; Malone KE; Porter PL; Daling JR; Li CI
    Cancer; 2008 Oct; 113(7):1521-6. PubMed ID: 18726992
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.